Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 8/20 | 0.53 |
| ▸ | CD274 | Q9NZQ7 | 8/20 | 0.53 |
| ▸ | MME | P08473 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ACP3 | P15309 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1190016 | 1.00 | PDCD1 (0.53) | PDCD1CD274MMEGAAMAPT | |
| SCHEMBL1190014 | 1.00 | PDCD1 (0.53) | PDCD1CD274MMEGAAMAPT | |
| Hydrochloric Acid SCHEMBL1008304 | 0.98 | PDCD1 (0.52) | PDCD1CD274MMEGAAMAPT | |
| Hydrochloric Acid SCHEMBL28545141 | 0.98 | PDCD1 (0.52) | PDCD1CD274MMEGAAMAPT | |
| Hydrochloric Acid SCHEMBL1008301 | 0.98 | PDCD1 (0.52) | PDCD1CD274MMEGAAMAPT | |
| Hydrazine SCHEMBL28609493 | 0.96 | PDCD1 (0.51) | PDCD1CD274MMEGAAMAPT | |
| SCHEMBL1576808 | 0.85 | PDCD1 (0.49) | PDCD1CD274ACP3ALDH1A1RAB9A | |
| SCHEMBL5653982 | 0.85 | PDCD1 (0.49) | PDCD1CD274ACP3ALDH1A1RAB9A | |
| SCHEMBL21274596 | 0.85 | GGT1 (0.47) | GAAMAPTPOLBACP3ALDH1A1 | |
| SCHEMBL28091682 | 0.85 | PDCD1 (0.48) | PDCD1CD274MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117986222-A | Biphenyl seven-membered ring compound and preparation method and application thereof | 华侨大学 | 2024-05-07 | — | — | CN | claimed |
| EP-4313173-A1 | PURIFICATION OF SUBSTITUTED DIAMINOPYRAZINE DICARBOXYLIC ACIDS | MediBeacon Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| CN-117222438-A | Purification of substituted diaminopyrazine dicarboxylic acids | 麦迪贝肯有限公司 | 2023-12-12 | — | — | CN | claimed |
| US-20220315538-A1 | PURIFICATION OF SUBSTITUTED DIAMINOPYRAZINE DICARBOXYLIC ACIDS | MEDIBEACON INC. | 2022-10-06 | — | — | US | claimed |
| WO-2022212080-A1 | PURIFICATION OF SUBSTITUTED DIAMINOPYRAZINE DICARBOXYLIC ACIDS | MEDIBEACON INC. (US) | 2022-10-06 | — | — | WO | claimed |
| CN-112979562-B | Benzo aromatic heterocyclic compound and application thereof | 华侨大学 | 2022-08-26 | — | — | CN | claimed |
| US-20050261372-A1 | Derivatives of glycinergic r(+)-2-amino-3-hydroxypropanoic acid | ORAPHARMA, INC. | 2005-11-24 | — | — | US | claimed |
| EP-1529030-A2 | DERIVATIVES OF GLYCINERGIC R(+)-2-AMINO-3-HYDROXYPROPANOIC ACID | Prestwick Pharmaceuticals, Inc. (US) | 2005-05-11 | — | — | EP | claimed |
| WO-2004016580-A2 | DERIVATIVES OF GLYCINERGIC R(+)-2-AMINO-3-HYDROXYPROPANOIC ACID | PRESTWICK PHARMACEUTICALS, INC. (US) | 2004-02-26 | — | — | WO | claimed |
| US-12428382-B2 | Purification of substituted diaminopyrazine dicarboxylic acids | MEDIBEACON INC. (US) | 2025-09-30 | — | — | US | disclosed |
| CN-119562806-A | Lipid nanoparticles for delivery of nucleic acids and methods of use thereof | 阿卡格拉医药公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-113966329-B | Heterocyclic immunomodulators as PDL1 checkpoint inhibitors | 爱尔兰詹森科学公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-117986222-A | Biphenyl seven-membered ring compound and preparation method and application thereof | 华侨大学 | 2024-05-07 | — | — | CN | disclosed |
| EP-4313173-A1 | PURIFICATION OF SUBSTITUTED DIAMINOPYRAZINE DICARBOXYLIC ACIDS | MediBeacon Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-0333154-B1 | Process for the preparation of cephem derivatives | EISAI CO LTD (JP) | 1997-07-16 | — | — | EP | disclosed |
| EP-0764648-A1 | Cephem derivatives and process for the preparation thereof | Eisai Co., Ltd. (JP) | 1997-03-26 | — | — | EP | disclosed |
| US-5610153-A | ENZYME INHIBITORS; TREATMENT OF VASCULAR PROLIFERATION DISORDERS, STERILITY DYSFUNCTION, DYSMENORRHEA | CIBA-GEIGY CORPORATION (US) | 1997-03-11 | — | — | US | disclosed |
| EP-0612751-A2 | Compounds for the preparation of cephem derivatives | Eisai Co., Ltd. (JP) | 1994-08-31 | — | — | EP | disclosed |
| US-5128465-A | Containing thiadiazole ring and fluorine substitution | EISAI CO., LTD. (JP) | 1992-07-07 | — | — | US | disclosed |
| EP-0333154-A2 | Process for the preparation of cephem derivatives and intermediates therefor | Eisai Co., Ltd. (JP) | 1989-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315538-A1 | PURIFICATION OF SUBSTITUTED DIAMINOPYRAZINE DICARBOXYLIC ACIDS | DDC, SDHA, IDH1 | PDCD1 950/4885CD274 2643/4885MME 4062/4885 |
| US-20050261372-A1 | Derivatives of glycinergic r(+)-2-amino-3-hydroxypropanoic acid | GLRA3, GLRA1, GLRA2 | PDCD1 4863/4885CD274 4870/4885MME 1356/4885 |
| US-12428382-B2 | Purification of substituted diaminopyrazine dicarboxylic acids | DDC, SDHA, IDH1 | PDCD1 950/4885CD274 2643/4885MME 4062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.